FINNENCE ▪ THE WIRE FILE
THE WIRE · № 68990
News■ Unclear/unknown
Mentara Therapeutics Launches to Advance MTA-304, a Phase 2-Ready PDE10A Inhibitor, for Levodopa-Induced Dyskinesia in Parkinson's Disease
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-07 12:00 UTC
LAST UPDATE2026-10-07 12:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A new company launch with a Phase 2-ready asset is early-stage and not linked to a listed ticker.
Early-stage neuropsychiatry startup, not investable
CATALYST TO WATCH
Phase 2 trial initiation in 2027
MAIN RISK
Long development timeline, binary outcomes
FULL DISPATCH
-SPRIM Global Investments-backed company acquires asset from EuMentis Therapeutics- - Phase 2 study planned for first half of 2027- SAN DIEGO and SYDNEY, Oct. 7, 2026 /PRNewswire/ -- Mentara Therapeutics, a new neuropsychiatry company backed by SPRIM Global Investments, today launched...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
MimiVax and Roswell Park Announce Results from Phase 2b SURVIVE Trial of SurVaxM in Newly Diagnosed Glioblastoma2026-10-07 12:00 UTC
MimiVax and Roswell Park Announce Results from Phase 2b SURVIVE Trial of SurVaxM in Newly Diagnosed Glioblastoma2026-10-07 12:00 UTC
→CORRELATIONshares Healthcare
Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting2026-10-07 12:00 UTC
Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting2026-10-07 12:00 UTC
→CORRELATIONshares Healthcare
Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds2026-10-07 12:02 UTC
Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds2026-10-07 12:02 UTC
→CORRELATIONshares Healthcare
Where to Invest $100,000: Healthcare, AI and High-Quality Bonds2026-10-07 11:00 UTC
Where to Invest $100,000: Healthcare, AI and High-Quality Bonds2026-10-07 11:00 UTC
→CORRELATIONshares Healthcare
Manufacturing Bispecific Antibodies: Development & Scale-Up, Upcoming Webinar Hosted by Xtalks2026-10-07 12:30 UTC
Manufacturing Bispecific Antibodies: Development & Scale-Up, Upcoming Webinar Hosted by Xtalks2026-10-07 12:30 UTC
→CORRELATIONshares Healthcare
FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body2026-10-07 12:30 UTC
FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body2026-10-07 12:30 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.